Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
10 06 2021
Historique:
received: 22 04 2021
revised: 28 05 2021
accepted: 04 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 16 7 2021
Statut: epublish

Résumé

SARS-CoV-2 infection fatality ratios (IFR) remain controversially discussed with implications for political measures. The German county of Tirschenreuth suffered a severe SARS-CoV-2 outbreak in spring 2020, with particularly high case fatality ratio (CFR). To estimate seroprevalence, underreported infections, and IFR for the Tirschenreuth population aged ≥14 years in June/July 2020, we conducted a population-based study including home visits for the elderly, and analyzed 4203 participants for SARS-CoV-2 antibodies via three antibody tests. Latent class analysis yielded 8.6% standardized county-wide seroprevalence, a factor of underreported infections of 5.0, and 2.5% overall IFR. Seroprevalence was two-fold higher among medical workers and one third among current smokers with similar proportions of registered infections. While seroprevalence did not show an age-trend, the factor of underreported infections was 12.2 in the young versus 1.7 for ≥85-year-old. Age-specific IFRs were <0.5% below 60 years of age, 1.0% for age 60-69, and 13.2% for age 70+. Senior care homes accounted for 45% of COVID-19-related deaths, reflected by an IFR of 7.5% among individuals aged 70+ and an overall IFR of 1.4% when excluding senior care home residents from our computation. Our data underscore senior care home infections as key determinant of IFR additionally to age, insufficient targeted testing in the young, and the need for further investigations on behavioral or molecular causes of the fewer infections among current smokers.

Identifiants

pubmed: 34200766
pii: v13061118
doi: 10.3390/v13061118
pmc: PMC8230374
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Bavarian States Ministry of Science and Arts (Freestate of Bavaria, Germany)
Organisme : National Research Network of the University Medicine (Germany)

Références

Bull World Health Organ. 2021 Jan 1;99(1):19-33F
pubmed: 33716331
Epidemiol Infect. 2018 Dec;146(16):2079-2085
pubmed: 30136643
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
Infection. 2021 Feb;49(1):75-82
pubmed: 32827125
Am J Epidemiol. 2014 Feb 15;179(4):423-31
pubmed: 24272278
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33571106
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Cell Host Microbe. 2021 Jun 9;29(6):917-929.e4
pubmed: 33984285
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Lancet Infect Dis. 2020 Aug;20(8):920-928
pubmed: 32422201
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9):
pubmed: 33571105
Struct Equ Modeling. 2007;14(4):671-694
pubmed: 19953201
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Int J Environ Res Public Health. 2020 Dec 21;17(24):
pubmed: 33371358
Dtsch Arztebl Int. 2020 Dec 11;117(50):861-867
pubmed: 33295275
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628
Biometrics. 2000 Dec;56(4):1055-67
pubmed: 11129461
Epidemiol Infect. 2020 Oct 13;148:e252
pubmed: 33046173
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347

Auteurs

Ralf Wagner (R)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

David Peterhoff (D)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Stephanie Beileke (S)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Felix Günther (F)

Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Geschwister-Scholl-Platz 1, 80539 Munich, Germany.
Department of Genetic Epidemiology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Melanie Berr (M)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Sebastian Einhauser (S)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Anja Schütz (A)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Hans Helmut Niller (HH)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Philipp Steininger (P)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Antje Knöll (A)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Matthias Tenbusch (M)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Clara Maier (C)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Klaus Korn (K)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Klaus J Stark (KJ)

Department of Genetic Epidemiology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

André Gessner (A)

Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Ralph Burkhardt (R)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Michael Kabesch (M)

University Children's Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg, Steinmetzstraße 1-3, 93049 Regensburg, Germany.

Holger Schedl (H)

Bayerisches Rotes Kreuz, Kreisverband Tirschenreuth, Egerstraße 21, 95643 Tirschenreuth, Germany.

Helmut Küchenhoff (H)

Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Geschwister-Scholl-Platz 1, 80539 Munich, Germany.

Annette B Pfahlberg (AB)

Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Waldstr. 6, 91054 Erlangen, Germany.

Iris M Heid (IM)

Department of Genetic Epidemiology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.

Olaf Gefeller (O)

Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Waldstr. 6, 91054 Erlangen, Germany.

Klaus Überla (K)

Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH